POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study

Martha L. Arellano; Michael J. Thirman; John F. DiPersio; Maël Heiblig; Eytan M. Stein; Andre C. Schuh; Andrius Žučenka; Stéphane De Botton; Carolyn S. Grove; Gabriel N. Mannis; Cristina Papayannidis; Alexander E. Perl; Ghayas C. Issa; Ibrahim Aldoss; Ashish Bajel; David S. Dickens; MichaelW.M. Kühn; Ioannis Mantzaris; Emmanuel Raffoux; Elie Traer; Irina Amitai; Hartmut Döhner; Corinna Greco; Tibor Kovacsovics; Christine M. McMahon; Pau Montesinos; Arnaud Pigneux; Paul J. Shami; Richard M. Stone; Ofir Wolach; John G. Harpel; Yakov Chudnovsky; Li Yu; Rebecca G. Bagley; Angela R. Smith; James S. Blachly

doi:10.1016/S2152-2650(25)00488-4

$POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study$

Abstract

Peer reviewed

POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study

Martha L. Arellano, Michael J. Thirman, John F. DiPersio, Maël Heiblig, Eytan M. Stein, Andre C. Schuh, Andrius Žučenka, Stéphane De Botton, Carolyn S. Grove, Gabriel N. Mannis, …

Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S180-S181

09/2025

DOI: 10.1016/S2152-2650(25)00488-4

View Online

Details

Title: Subtitle: POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study
Creators: Martha L. Arellano - Winship Cancer Institute
Michael J. Thirman - University of Chicago
John F. DiPersio - Washington University in St. Louis School of Medicine
Maël Heiblig - Hôpital Lyon Sud
Eytan M. Stein - Memorial Sloan Kettering Cancer Center
Andre C. Schuh - University of Toronto
Andrius Žučenka - Vilnius University
Stéphane De Botton - Institut Gustave Roussy
Carolyn S. Grove - Sir Charles Gairdner Hospital
Gabriel N. Mannis - Stanford University School of Medicine
Cristina Papayannidis - IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Alexander E. Perl - University of Pennsylvania
Ghayas C. Issa - The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss - City Of Hope National Medical Center
Ashish Bajel - The University of Melbourne
David S. Dickens - University of Iowa
MichaelW.M. Kühn - University Medical Center of the Johannes Gutenberg University Mainz
Ioannis Mantzaris - Montefiore Einstein Comprehensive Cancer Center
Emmanuel Raffoux - Université Paris Cité
Elie Traer - OHSU Knight Cancer Institute
Irina Amitai - Sheba Medical Center
Hartmut Döhner - University Hospital Ulm
Corinna Greco - Ospedale San Bortolo
Tibor Kovacsovics - City Of Hope National Medical Center
Christine M. McMahon - University of Colorado Anschutz Medical Campus
Pau Montesinos - Hospital Universitari i Politècnic La Fe
Arnaud Pigneux - Centre Hospitalier Universitaire de Bordeaux
Paul J. Shami - University of Utah
Richard M. Stone - Dana-Farber Cancer Institute
Ofir Wolach - Tel Aviv University
John G. Harpel - ICON plc, Blue Bell, PA, USA
Yakov Chudnovsky - Syndax Pharmaceuticals, Inc., New York, NY, USA
Li Yu - Syndax Pharmaceuticals, Inc., New York, NY, USA
Rebecca G. Bagley - Syndax Pharmaceuticals, Inc., New York, NY, USA
Angela R. Smith - Syndax Pharmaceuticals, Inc., New York, NY, USA
James S. Blachly - The Ohio State University
Resource Type: Abstract
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S180-S181
DOI: 10.1016/S2152-2650(25)00488-4
ISSN: 2152-2650
Publisher: Elsevier Inc
Language: English
Date published: 09/2025
Academic Unit: Stead Family Department of Pediatrics; Hematology/Oncology
Record Identifier: 9984949518102771

Metrics

9 Record Views